Cargando…

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohandas, Sreelekshmy, Yadav, Pragya D., Shete-Aich, Anita, Abraham, Priya, Vadrevu, Krishna Mohan, Sapkal, Gajanan, Mote, Chandrashekhar, Nyayanit, Dimpal, Gupta, Nivedita, Srinivas, Vellimedu Kannappa, Kadam, Manoj, Kumar, Abhimanyu, Majumdar, Triparna, Jain, Rajlaxmi, Deshpande, Gururaj, Patil, Savita, Sarkale, Prasad, Patil, Deepak, Ella, Raches, Prasad, Sai D., Sharma, Sharda, Ella, Krishna M., Panda, Samiran, Bhargava, Balram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829205/ https://www.ncbi.nlm.nih.gov/pubmed/33521604 http://dx.doi.org/10.1016/j.isci.2021.102054

Ejemplares similares

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
por: Yadav, Pragya D., et al.
Publicado: (2021)

Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
por: Nyayanit, Dimpal A., et al.
Publicado: (2021)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Transcriptome & viral growth analysis of SARS-CoV-2-infected Vero CCL-81 cells
por: Nyayanit, Dimpal A., et al.
Publicado: (2020)

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model
por: Yadav, Pragya, et al.
Publicado: (2022)

Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants
por: Patil, Dilip R., et al.
Publicado: (2023)

Inactivation of SARS-CoV-2 by gamma irradiation
por: Jain, Rajlaxmi, et al.
Publicado: (2021)

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
por: Ganneru, Brunda, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection
por: Mohandas, Sreelekshmy, et al.
Publicado: (2020)

Genomic characterization, transcriptome analysis, and pathogenicity of the Nipah virus (Indian isolate)
por: Mohandas, Sreelekshmy, et al.
Publicado: (2023)

SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
por: Ella, Raches, et al.
Publicado: (2021)

Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens
por: Yadav, Pragya D., et al.
Publicado: (2022)

Authors’ response
por: Mukhopadhyay, Labanya, et al.
Publicado: (2021)

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
por: Mukhopadhyay, Labanya, et al.
Publicado: (2021)

Characterization of a strain of quaranfil virus isolated from soft ticks in India. Is quaranfil virus an unrecognized cause of disease in human and animals?”
por: Mourya, Devendra T., et al.
Publicado: (2019)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022)

Identification and phylogenetic analysis of herpes simplex virus-1 from clinical isolates in India
por: Nyayanit, Dimpal A., et al.
Publicado: (2019)

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
por: Yadav, Pragya D., et al.
Publicado: (2022)

Clinico-epidemiological investigation on Varicella Zoster Virus indicates multiple clade circulation in Maharashtra state, India
por: Sahay, Rima R., et al.
Publicado: (2018)

Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers
por: Yadav, Pragya D., et al.
Publicado: (2022)

Study of Kyasanur forest disease viremia, antibody kinetics, and virus infection in target organs of Macaca radiata
por: Patil, Dilip R., et al.
Publicado: (2020)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern
por: Dighe, Hitesh, et al.
Publicado: (2022)

First isolation of SARS-CoV-2 from clinical samples in India
por: Sarkale, Prasad, et al.
Publicado: (2020)

SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
por: Sahay, Rima R., et al.
Publicado: (2022)

Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees
por: Yadav, Pragya D., et al.
Publicado: (2022)

Molecular characterization & recombination analysis of complete enterovirus-88 isolated from acute flaccid paralysis cases in India
por: Munivenkatappa, Ashok, et al.
Publicado: (2023)

Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India
por: Potdar, Varsha, et al.
Publicado: (2020)

A qualitative IgG ELISA for detection of SARS-CoV-2-specific antibodies in Syrian hamster serum samples
por: Shete, Anita, et al.
Publicado: (2021)

Detection of coronaviruses in Pteropus & Rousettus species of bats from different States of India
por: Yadav, Pragya D., et al.
Publicado: (2020)

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2019)

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India
por: Reddy, Raghu, et al.
Publicado: (2021)

Comparative pathogenicity of BA.2.12, BA.5.2 and XBB.1 with the Delta variant in Syrian hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2023)

Quasispecies analysis of the SARS-CoV-2 from representative clinical samples: A preliminary analysis
por: Nyayanit, Dimpal A., et al.
Publicado: (2020)

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India
por: Ella, Raches, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vh0b6shru718homfu2pmoubh6a